Caribou Biosciences (CRBU) Jefferies Global Healthcare Conference 2025 summary

Platform and program overview

• Proprietary next-generation CRISPR (chRDNA) technology is used to develop two off-the-shelf CAR-T cell therapies for lymphoma (CB-010) and myeloma (CB-011), both in clinical stages.

• CB-010 aims to match the efficacy of autologous CAR-Ts in lymphoma, with ongoing studies showing promising long-term responses.

• CB-011 for multiple myeloma will have its first data set released in the second half of the year, with early signs of encouraging efficacy.

Industry landscape and unmet needs

• Only 20% of lymphoma and 10% of myeloma patients access commercial autologous CAR-Ts, leaving a large unmet need.

• Allogeneic CAR-Ts offer rapid, off-the-shelf access, addressing issues of disease progression speed and limited access at community clinics.

Clinical development and data disclosure plans

• Data updates for both programs will be disclosed via corporate events in the second half of the year.

• For CB-010, a 20-patient cohort with partial HLA matching (≥4 alleles) is fully enrolled, with most patients at least six months post-dosing.

• Data will focus on overall response rate (ORR), complete response (CR), progression-free survival (PFS), and durability, guiding go/no-go decisions for pivotal trials.

• An additional 10-patient cohort includes those relapsed after prior CD19 therapy, with data to be shared later this year.